Literature DB >> 3982731

Misstaging of ovarian cancer.

L McGowan, L P Lesher, H J Norris, M Barnett.   

Abstract

The thoroughness of intraoperative evaluation of the extent of disease in 291 women with primary ovarian cancer was investigated. Notable differences among physician specialties but not types of hospitals where initial surgery was performed were observed. A review of medical record documentation revealed that 97% of the cases operated on by gynecologic oncologists had complete staging evaluations performed intraoperatively, but only 52 and 35% of cases operated on by obstetricians/gynecologists and general surgeons, respectfully, were adequately evaluated. Roughly one-half of the cases diagnosed in community hospitals and in hospitals with teaching affiliations were found to be completely studied, and 66% of those operated on in university hospitals received complete intraoperative evaluations.

Entities:  

Mesh:

Year:  1985        PMID: 3982731

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  17 in total

1.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; Moune Jabre-Raughley; Amy K Brown; Katina M Robison; M Craig Miller; W Jeffery Allard; Robert J Kurman; Robert C Bast; Steven J Skates
Journal:  Am J Obstet Gynecol       Date:  2010-05-14       Impact factor: 8.661

Review 2.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

Review 3.  Management of early carcinoma of the ovary.

Authors:  G W Chapman
Journal:  J Natl Med Assoc       Date:  1988-09       Impact factor: 1.798

Review 4.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

5.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

6.  Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States.

Authors:  Shamly Austin; Michelle Y Martin; Yongin Kim; Ellen M Funkhouser; Edward E Partridge; Maria Pisu
Journal:  Health Serv Res       Date:  2012-12-03       Impact factor: 3.402

Review 7.  Current state of biomarker development for clinical application in epithelial ovarian cancer.

Authors:  Richard G Moore; Shannon MacLaughlan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

8.  Malignant endometrioid cystadenofibroma of the ovary.

Authors:  D H Moore; W C Fowler; P J Santrach
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

Review 9.  Early ovarian cancer.

Authors:  G Coukos; S C Rubin
Journal:  Curr Treat Options Oncol       Date:  2000-06

Review 10.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.